Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Dogwood Therapeutics Q3 2026 Results: Net Loss of $4.88M, Loss Narrows

Dogwood Therapeutics reported a net loss of $21.4 million for the nine months ended September 30, 2026, which included a $9.2 million impairment charge related to IPR&D. The company ended the period with $4.9 million in cash and cash equivalents, down from $6.5 million at the end of 2025.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue0.1—
Gross profit0.0—
Profit before tax-4.9-15.7
Net income-4.9-15.7
EPS (diluted, $ a share)$-0.14$-8.20

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Gross margin11.9%
Source

10-Q filed with the SEC, NASDAQ: DWTX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Dogwood Therapeutics, Inc.: key numbers

Share price
$1.08Close, Nov 17
Market cap
$41.3M
Shares outstanding
38.23MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Dogwood Therapeutics, Inc.

All →
8:46 AM ET 8-K
Financial Results

Dogwood Therapeutics Financial Results

Dogwood Therapeutics reported third quarter 2026 financial results, highlighting the completion of its Halneuron Phase 2b trial for chemotherapy-induced neuropathic pain with top-line results expected in November 2026. The company also closed a $5 million private placement with Sealbond Limited to fund Phase 3 preparatory activities, extending its cash runway into the first quarter of 2027.

Term
3 months

“With results from the recently completed Phase 2b CINP study to be reported in November, we believe that if successful, Halneuron® could represent the first new therapeutic agent for millions of CINP patients in the US and tens of millions of CINP patients across the globe.”

Greg Duncan, Chief Executive Officer of Dogwood Therapeutics
8:45 AM ET 8-K
Capital Raise

Dogwood Therapeutics Capital Raise of $5M

Dogwood Therapeutics entered into a subscription agreement to sell 4,098,360 shares of common stock to its largest shareholder, Sealbond Limited (a subsidiary of CK Life Sciences), in a $5 million private placement. The proceeds will be used to fund Phase 3 preparatory activities for Halneuron® and extend the company's operational runway through March 2027.

Value
$5M
Counterparty
Sealbond Limited

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.